Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

被引:27
|
作者
Leung, Ella H. [1 ,2 ]
Oh, Daniel J. [1 ]
Alderson, Shannon E. [1 ]
Bracy, Joshlynn [1 ]
McLeod, Mia [1 ]
Perez, Litzi, I [1 ]
Bottini, Alexander [1 ]
Yee, David Chin [1 ]
Mukkamala, Krishna [1 ]
机构
[1] Georgia Retina, Atlanta, GA USA
[2] 833 Campbell Hill St NW, Suite 300, Marietta, GA 30060 USA
来源
CLINICAL OPHTHALMOLOGY | 2023年 / 17卷
关键词
faricimab; intravitreal injection; neovascular age-related macular degeneration; intraocular inflammation; anti-vascular endothelial growth factor;
D O I
10.2147/OPTH.S409822
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the initial efficacy and safety of intravitreal faricimab in eyes previously treated for neovascular age-related macular degeneration (nARMD).Patients and methods: A retrospective review of all patients with nARMD previously treated with anti-vascular endothelial growth factor (anti-VEGF) injections who received at least 3 intravitreal faricimab injections with at least 3 months of follow-up.Results: A total of 190 eyes were included. Patients received a mean of 34.2 +/- 23 anti-VEGF injections over 182.41 +/- 128 weeks prior to switching to faricimab. Patients then received a mean of 6.99 +/- 2.3 faricimab injections with an average 34.88 +/- 8.2 weeks of follow-up. The mean best corrected visual acuities improved from 0.33 +/- 0.32 logMAR approximate to 20/43 to 0.27 +/- 0.32 logMAR approximate to 20/37 (P=0.0022). The central subfield thickness (CST) improved from 312 +/- 87 mu m to 287 +/- 71 mu m (P<0.0001). At the last clinical visit, 24% had no subretinal fluid or intraretinal fluid on optical coherence tomography. The mean dosing interval between the last two consecutive faricimab injections (7.64 +/- 6.2 weeks) was significantly longer than that for ranibizumab (5.16 +/- 2.0 weeks, P<0.001) or aflibercept (5.57 +/- 3.6 weeks, P<0.001). No patients developed idiopathic intraocular inflammation.Conclusion: Intravitreal faricimab was associated with improved vision and CSTs, even in treatment-resistant nARMD eyes. The mean last dosing interval for faricimab was longer than for ranibizumab or aflibercept. No significant adverse events were directly attributed to faricimab during the study.
引用
收藏
页码:1287 / 1293
页数:7
相关论文
共 50 条
  • [31] One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
    Rush, Ryan B.
    [J]. CLINICAL OPHTHALMOLOGY, 2023, 17 : 2201 - 2208
  • [32] Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)
    Giancipoli, Ermete
    Guglielmi, Antonella
    Bux, Anna Valeria
    Clima, Giulia Maria Emilia
    Pignatelli, Francesco
    Boscia, Francesco
    Viggiano, Pasquale
    Boscia, Giacomo
    Fortunato, Francesca
    Besozzi, Gianluca
    Niro, Alfredo
    Dore, Stefano
    Iaculli, Cristiana
    [J]. OPHTHALMOLOGY AND THERAPY, 2024, : 2163 - 2184
  • [33] Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
    Kikuchi, Yusuke
    Kawczynski, Michael G.
    Anegondi, Neha
    Neubert, Ales
    Dai, Jian
    Ferrara, Daniela
    Quezada-Ruiz, Carlos
    [J]. OPHTHALMOLOGY SCIENCE, 2024, 4 (02):
  • [34] Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    He, Lingmin
    Silva, Ruwan A.
    Ayoub, Noel
    Moshfeghi, Darius M.
    Leng, Theodore
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (05): : 542 - 549
  • [35] Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
    Gharbiya, Magda
    Iannetti, Ludovico
    Parisi, Francesco
    De Vico, Umberto
    Mungo, Maria Laura
    Marenco, Marco
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [36] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [37] First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration
    Aljundi, Wissam
    Daas, Loay
    Suffo, Shady
    Seitz, Berthold
    Abdin, Alaa Din
    [J]. PHARMACEUTICS, 2024, 16 (04)
  • [38] The impact of treatment intensity over 3 years of real-world data of neovascular age-related macular degeneration
    Gkorou, Olga
    Duncan, Holly
    Hogg, Jeffry
    Stone, Lydia
    Blyth, Michelle
    Brandes, Lesley
    Devenport, Adele
    Timms, Leanne
    Talks, James
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [39] Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study
    Gabriela Grimaldi
    Giuseppe Cancian
    Angelica Rizzato
    Alex Casanova
    Kathrin Perruchoud-Ader
    Michele Clerici
    Andrea Consigli
    Moreno Menghini
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262 : 1151 - 1159
  • [40] Artificial intelligence to identify conventional treatment patterns in neovascular age-related macular degeneration in a real-world population
    Leolino Mares, Virginia De Souza
    Bogunovic, Hrvoje
    Leingang, Oliver
    Barthelmes, Daniel
    Reiter, Gregor Sebastian
    Schmidt-Erfurth, Ursula
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)